[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"glucagon\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:glucagon":44},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100619891",false,"NCT07350512","Investigating the Acute Effects of Increasing Alanine Exposure in Healthy Participants","Investigating the Effect of Glucagon on Cognitive Function and Cerebral Glucose Metabolism in Humans: A Pilot Study","Inclusion Criteria:\n\n* Capable of understanding the participant information and signing the consent form\n* Between 25 and 70 years of age at the time of screening\n* Body mass index (BMI) ≤ 25 kg\u002Fm2 at the time of screening\n\nExclusion Criteria:\n\n* Enrolment in other research projects that might interfere with the study\n* Diabetes diagnosis (type 1 and 2)\n* Pregnancy or breastfeeding\n* Use of medications which, in the opinion of the investigator, may jeopardise participant's safety or compliance with the protocol\n* Impaired liver function defined as either alanine aminotransferase (ALAT) and\u002For aspartate aminotransferase (ASAT) ≥ 2 times normal values\n* Kidney disease defined as serum creatinine levels ≥ 126 μmol\u002FL for male and ≥ 111 μmol\u002FL for female\n* Inadequately treated blood pressure at screening defined as repeated resting blood pressure outside the range 90-150 mmHg for systolic and 50-100 mmHg for diastolic\n* Active or recent malignant disease\n* Current or history of severe alcohol use or drug\u002Fchemical abuse as per investigator's judgement\n* Any chronic disorders or severe diseases which, in the opinion of the investigator, might jeopardise participant's safety or compliance with the protocol",true,"ALL","25 Years","70 Years",{"count":20,"type":21},15,"ESTIMATED","INTERVENTIONAL",[24],"NA","In this study the investigators will investigate the acute effects of increasing alanine exposure on metabolic parameters in healthy participants.\n\nParticipants will participate in one study day. After initial baseline blood samples, a three-hour intravenous infusion with glucagon will be initiated. The infusion rate will be increased every 30 minutes.",[27,28],"Glucose Metabolism","Glucagon",[30,31,32],"Alanine","glucagon","glucose metabolism","NOT_YET_RECRUITING","2026-01-09",{"date":36,"type":37},"2026-01-20","ACTUAL",{"date":36,"type":21},{"date":40,"type":21},"2027-01-20",{"name":42,"class":43},"Nicolai Jacob Wewer Albrechtsen","OTHER",""]